Shimoni Zvi, Cohen Regev, Avdiaev Ruslan, Froom Paul
Department of Internal Medicine B, Laniado Hospital, Netanya, Israel.
Ruth and Bruce Rappaport School of Medicine, Haifa, Israel.
BMJ Open. 2016 Dec 16;6(12):e013696. doi: 10.1136/bmjopen-2016-013696.
To determine the consequences of treating febrile geriatric patients with a suspected urinary tract infection (UTI) with antibiotics that have high resistance rates due primarily to extended-spectrum β-lactamase (ESBL) producing bacteria.
In this cohort study, we selected 257 consecutive hospitalised patients aged ≥70 years with a chief symptom of fever, possibly due to a UTI and initially treated with antibiotics with rates in our hospital of urinary culture resistance >20%. Patients with severe sepsis were excluded. The main outcomes measures were in vitro bacterial resistance to initial antibiotic therapy (BRIAT), response to therapy, hospitalisation days and mortality.
Urine cultures were positive in 64.2% (165 of 257) of the patients and BRIAT occurred in 28.0% (72 of 257). Response rates were 100% (93 of 93) in those with bacteria sensitive to initial antibiotic therapy, 95.7% (88 of 92) in the culture negative patients, and 66.7% (48 of 72) in those with BRIAT (p<0.001). There were no deaths due to deterioration during the initial treatment period because of BRIAT. In the patients with BRIAT, the median length of hospitalisation was 3 days longer than that in the other patients (7 and 4 days, respectively, p<0.001).
We conclude that initial broad spectrum antibiotic treatment could potentially lower the median length of hospitalisation by 3 days in many hospitalised geriatric patients without an extra-urinary tract source for their fever. This benefit needs to be balanced against the risk to the individual patient and to the general public of increasing bacterial resistance rates to broader spectrum antibiotics often held in reserve.
确定使用主要因产超广谱β-内酰胺酶(ESBL)细菌而耐药率高的抗生素治疗疑似尿路感染(UTI)的发热老年患者的后果。
在这项队列研究中,我们选取了257例连续住院的年龄≥70岁的患者,其主要症状为发热,可能因UTI所致,且最初接受了我院尿培养耐药率>20%的抗生素治疗。排除严重脓毒症患者。主要结局指标为体外细菌对初始抗生素治疗的耐药性(BRIAT)、治疗反应、住院天数和死亡率。
64.2%(257例中的165例)患者尿培养呈阳性,28.0%(257例中的72例)发生BRIAT。初始抗生素治疗敏感细菌患者的反应率为100%(93例中的93例),培养阴性患者为95.7%(92例中的88例),BRIAT患者为66.7%(72例中的48例)(p<0.001)。在初始治疗期间,没有因BRIAT导致病情恶化而死亡的情况。在发生BRIAT的患者中,住院中位时间比其他患者长3天(分别为7天和4天,p<0.001)。
我们得出结论,对于许多无尿路外发热源的住院老年患者,初始广谱抗生素治疗可能会使住院中位时间缩短3天。这种益处需要与个体患者以及因储备的更广谱抗生素细菌耐药率增加而给公众带来的风险相权衡。